StockNews.com initiated coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) in a research note published on Thursday morning. The brokerage issued a sell rating on the stock.
MBRX has been the topic of several other reports. Maxim Group downgraded shares of Moleculin Biotech from a “buy” rating to a “hold” rating in a report on Wednesday, February 12th. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Moleculin Biotech in a report on Monday, March 3rd.
Check Out Our Latest Analysis on MBRX
Moleculin Biotech Stock Down 2.6 %
About Moleculin Biotech
Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.
Recommended Stories
- Five stocks we like better than Moleculin Biotech
- Trading Halts Explained
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.